Early serum TARC reduction predicts prognosis in advanced‐stage Hodgkin lymphoma patients treated with a PET‐adapted strategy
- 30 June 2020
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 38 (4) , 501-508
Abstract
Among patients with advanced‐stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET‐2) has prognostic value. However, 15% of patients with a negative PET‐2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation‐regulated chemokine (TARC) levels, to improve risk assessment in patients treated according to HD0607 PET‐driven trial (#NCT00795613). In 266 patients with available serum samples, who have agreed to participate in a sub‐study for assessment of the role of TARC monitoring, serum TARC levels were measured at baseline and at time of PET‐2 by commercially available ELISA test kits. The primary end‐point was to evaluate the association between TARC after 2 ABVD cycles and PFS. Median TARC‐2 values were significantly higher in PET‐2‐positive patients compared to PET‐2‐negative patients (P = .001), and in patients with treatment failure compared to those in continuous CR (P = .01). The 4‐year PFS significantly differed between patients with TARC‐2 >800 pg/mL vs ≤800 pg/mL (64% vs 86%, P = .0001). Moreover, among PET‐2‐negative patients, elevated TARC‐2 identified those with a worse prognosis (74% vs 89%; P = .01). In multivariable analysis, TARC‐2 >800 pg/mL was a significant independent predictor of PFS in the whole study population (HR 2.39, P = .004) and among the PET‐2‐negative patients (HR 2.49, P = .02). In conclusion, our results indicate that TARC‐2 serum levels above 800 pg/mL suggest the need for a stringent follow‐up in PET‐2‐negative patients, and the evaluation of new drugs in PET‐2‐positive, who will likely fail to respond to intensification with escalated BEACOPP.Keywords
This publication has 26 references indexed in Scilit:
- Serum Thymus and Activation-Regulated Chemokine Level Monitoring May Predict Disease Relapse Detected by PET Scan after Reduced-Intensity Allogeneic Stem Cell Transplantation in Patients with Hodgkin LymphomaTransplantation and Cellular Therapy, 2014
- Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin LymphomaClinical Cancer Research, 2013
- Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantLeukemia & Lymphoma, 2013
- Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin LymphomaClinical Cancer Research, 2013
- Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphomaAmerican Journal of Hematology, 2012
- Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphomaHaematologica, 2011
- Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytesBlood, 2008
- Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22British Journal of Haematology, 2008
- Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic FactorCancer Research, 2005
- High Expression of the CC Chemokine TARC in Reed-Sternberg CellsThe American Journal of Pathology, 1999